Today · announcement October 20

OpenAI to acquire Orchestra Bio; the price isn't disclosed

OpenAI announces it will acquire Orchestra Bio, a platform that helps biotech and pharma companies coordinate drug development; the price isn't disclosed. OpenAI's site describes Orchestra Bio as "a platform that helps biopharma teams coordinate the complex process of drug development," to be connected on top of Rosalind, OpenAI's own AI models and tools for life-sciences research (OpenAI, 2026-10-20). What OpenAI is buying is the workflow-coordination layer, not a drug-discovery model. The original doesn't give deal terms or Orchestra Bio's customer count or revenue. How we checked →

Concept illustration: a long light board in a dark grey frame shows, on the left, a white tile with a black interlaced knot-shaped symbol and the lettering OPENAI, and in the middle an empty dashed-outline slot above a grey card lettered ROSALIND that holds a speech bubble with grey lines. On the right, a large red panel lettered ORCHESTRA BIO with a ring-shaped symbol and a small cream tag hanging from its corner juts out past the frame; inside it, four circular icons (a flask, a test tube, a capsule and a clipboard) are joined by short dashes above a white plate lettered COORDINATION, and a curved dark arrow runs from the panel toward the empty dashed slot.

Source and checks

This item ran in the brief of Oct 21, 2026, alongside 15 other items. How we checked it, the quote checks and what was still missing that day are on that issue's How we checked page.

Cite this item

SecondSource (2026). "OpenAI to acquire Orchestra Bio; the price isn't disclosed." https://secondsource.io/en/product/2026-10-21-2/. Accessed access date.